IPQ Inside the global regulatory dialogue

FDA Tabling Public Biosimilar Discussions While Digesting Complexities of New Legislation

Jun 22nd, 2010

Please Log in to print the full article

FDA speakers at recent conferences have been open about their inability to discuss biosimilar issues at this time, while they digest the implications of the recently-passed Patient Protection and Affordable Care Act (PPACA).......

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications